Capecitabine-induced potentiation of warfarin [1]

Clinical Oncology

Volumn 15, Issue 5, 2003, Pages 297-298

  Buyck, H C E ^a   Buckley, N ^a   Leslie, M D ^a   Plowman, P N ^a  

^a Oncology Unit The Harley Street Clinic ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTICOAGULANT AGENT; CAPECITABINE; CYTOCHROME P450; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FRESH FROZEN PLASMA; HEMOGLOBIN; OMEPRAZOLE; OXALIPLATIN; PHENYTOIN; PRODRUG; SORIVUDINE; VITAMIN K GROUP; WARFARIN;

AGED; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CASE REPORT; COLON CANCER; DRUG POTENTIATION; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTERNATIONAL STANDARD UNIT; LETTER; LONG TERM CARE; MALE; METASTASIS; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; WARFARIN;

EID: 0042631317     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0936-6555(03)00111-0     Document Type: Letter

References (5)

1. Xeloda (capecitabine) tablets. European summary of product characteristics. 2001. Roche Ltd, Welwyn Garden City, UK.
2. Xeloda (capecitabine) tablets. US product information 2001. Roche Laboratories Inc. Nutley, New Jersey, USA.
3. Kolesar J, Johnson C, Freeberg B, et al. Warfarin-5-FU interaction - a consecutive case series. Pharmacotherapy 1999;19:1445-1449.
4. Blum J, Jones S, Buzdar A, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-493.
5. Sitkur Copur M, Ledakis P, Bolton M, et al. An adverse interaction between warfarin and capecitabine: a case report and review of the literature. Clin Colorectal Cancer 2001;1:182 184.